Clinical trials: Atopic Dermatitis, completed
Atopic Dermatitis Eczema
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
- Trial name
- NCT05579899
- Testing
- EVO101
- Where
- 21 sites in United States
- Volunteers
- 119 people
- Sponsor
- Evommune, Inc.
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.
The main purpose of this phase 2 study was to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.
- Trial name
- NCT04836858
- Testing
- CMK389
- Where
- 18 sites in Czechia, France and 4 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Emollients in the Management of Atopic Dermatitis
The purpose of this study is to confirm that emollients play a major role in the maintenance therapy after clearing of inflammatory lesions and can reduce occurrence of flares in children with atopic dermatitis.
- Trial name
- NCT01779258
- Testing
- glycerol, paraffin (liquid and white soft), Atopiclair®, Locatop@
- Where
- 15 sites in Estonia, France and 3 more
- Volunteers
- 347 people
- Sponsor
- Pierre Fabre Medicament
Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03985943
- Testing
- Nemolizumab
- Where
- 174 sites in United States, Australia and 12 more
- Volunteers
- 941 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118792
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults
The purpose is to study efficacy of Lactofiltrum in adult patients with atopic dermatitis. Lactofiltrum consists of 85% of hidrolytic lignin and 15% of lactulose and acts as an enterosorbent, which enables to enhance metabolism…
- Trial name
- LF-AD-09 (NCT01124318)
- Testing
- Lactofiltrum
- Where
- 2 sites in Russia
- Volunteers
- 90 people
- Sponsor
- Avva Rus, JSC
Healthy
Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants
This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants.
- Trial name
- NCT03796182
- Testing
- Metformin, PF-04965842
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis
The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment 0.1%, manufactured by Taro Pharmaceuticals Inc.
- Trial name
- NCT00833079
- Testing
- Tacrolimus 0.1% manufactured by Taro, Protopic - Tacrolimus 0.1%, Tacrolimus Vehicle manufactured by Taro
- Volunteers
- 500 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis (AD), Psoriasis
A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
Previously, the investigators have demonstrated in vitro the excellent efficacy of marula oil-derived ceramide NPs in enhancing skin barrier function.
- Conditions
- Atopic Dermatitis (AD), Psoriasis, Acne Vulgaris, Contact Dermatitis
- Trial name
- NCT07066150
- Testing
- Apply a cream containing 0.05% marula oil-derived ceramide NPs
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Shanghai Chicmax Cosmetic Co., Ltd.
Atopic Dermatitis
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects with mild to moderate AD.
- Trial name
- NCT03571620
- Testing
- Q301 Cream, Vehicle
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- Qurient Co., Ltd.
Dermatitis, Atopic
Pharmacokinetic Study of Topical GSK2894512 Cream
This study will assess the systemic exposure and pharmacokinetic parameters of GSK2894512 following twice daily topical administration of 1% and 2% cream in adult subjects with AD, and will provide information about the systemic…
- Trial name
- NCT02466152
- Testing
- GSK2894512 Topical Cream
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Measure Up 1 (NCT03569293)
- Testing
- Upadacitinib
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Atopic Dermatitis
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01639040
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 31 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately…
- Trial name
- NCT02755649
- Testing
- Dupilumab
- Where
- 73 sites in Austria, Belgium and 8 more
- Volunteers
- 325 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
- Trial name
- NCT01986933
- Testing
- nemolizumab (CIM331)
- Where
- 18 sites in United States
- Volunteers
- 264 people
- Sponsor
- Chugai Pharmaceutical
Atopic Dermatitis
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth.
- Trial name
- NCT07172321
- Testing
- PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in…
- Trial name
- NCT04562116
- Testing
- Nemolizumab, CYP 450 Substrates
- Where
- 6 sites in United States, Bulgaria
- Volunteers
- 17 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
Primary objective: To characterize the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment for adult AD patients, who are eligible for dupilumab reimbursement in Taiwan (e.g., used regimens, reason…
- Trial name
- NCT05442645
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
The purpose of this study is to see how a medicine called PF-08049820 affects how other medicines move through the body. This information will help plan future studies.
- Trial name
- NCT07190430
- Testing
- PF-08049820, Midazolam, Dabigatran Etexilate
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer